Business Wire

HONG-KONG-SCIENCE

24.3.2023 03:01:29 CET | Business Wire | Press release

Share
HKSTP Reveals Startup Semi-finalists for Annual Global EPiC Pitch Competition

Hong Kong is open to all and Hong Kong Science and Technology Parks Corporation (HKSTP) is ramping up its seventh Elevator Pitch Competition (EPiC 2023) by unveiling its 50 Grand Finale semi-finalists, selected from 618 entries and 55 economies across the world.

EPiC 2023 -- backed by innovation-driven partners Cathay, HSBC, MTR Lab, plus world-leading accelerator Plug & Play -- is the city’s most eagerly anticipated pitch event each year and will take place on 28 April 2023 (Friday) at the summit of Hong Kong’s tallest building, the International Commerce Centre. The annual event is a unique, worldwide competition for mid to late-stage startups in the FinTech and PropTech sectors who seek to expand their footprints into Asia and beyond, while leveraging Hong Kong’s biggest innovation ecosystem at HKSTP.

EPiC provides the best available platform for startups to make real business impact through connections with the Science Park network of 1,000+ investors and 300+ corporate partners.

This year, three quarters of the entries are from overseas, with the proportion of overseas contestants and the number of economies participating hitting a record high since 2016. A total of 50 contestants representing 14 different economies entered the semi-final round.

All 50 semi-finalists have a golden opportunity to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, as well as market expansion support across Asia and beyond, plus the chance to win a cash prize of US$90,000 if crowned overall champion.

Albert Wong, CEO, HKSTP, said: “EPiC is an iconic mega event that has hit global scale, as record turnout from international startups further demonstrates Hong Kong’s advantages as an international I&T hub. Hong Kong is diversified, vibrant and attracts the very best entrepreneurs, investors and corporate innovators. Grow fast and go beyond is the theme for EPiC this year, and we welcome talents from around the world to explore Hong Kong’s unlimited investment and innovation opportunities.”

The EPiC Grand Finale on 28 April will be hosted at Hong Kong’s iconic Sky 100 venue atop Hong Kong’s tallest building, the International Commerce Centre. The 50 competing teams will pitch their world-changing ideas to a judging panel of renowned investors, entrepreneurs, and business leaders. The actual pitch will comprise of a 60-second elevator ride as participants compete for the title of overall EPiC Champion.

To propel EPiC to the broader public, HKSTP has launched for the first time, the "My Favourite Pitcher" public poll, which is open to all to vote for their favourite pitch video from the shortlisted 50 semi-finalists. The poll is now available at EPiC polling website (epic-voting.hkstp.org) and lasts until 28 April 2023 1pm (HKT). The semi-finalist with the highest number of votes will win the cash prize of US$10,000, plus 200,000 Asia Miles sponsored by Cathay.

HKSTP will also kick off the exclusive Immersion Programme for semi-finalists to experience Hong Kong’s I&T ecosystem first-hand and unlock business opportunities through educational talks, business matching and networking with leading corporate partners and investors across the HKSTP ecosystem.

Contestants Breakdown:

Category

No. of applicants

PropTech

266 (43%)

FinTech

352 (57%)

Headquarter

No. of applicants

Overseas

465 (75%)

Hong Kong

153 (25%)

A record high proportion of overseas contestants and economies participation since 2016.

EPiC activities:

Now until 28 April 2023, 1pm (HKT)

"My Favourite Pitcher" Public Polling

  • The top 50 semi-finalists' pitching videos is open for public online voting
  • The semi-finalist with the highest number of votes will be crowned EPiC 2023's "My Favourite Pitcher" and win the cash prize of US$10,000 plus 200,000 Asia Miles sponsored by Cathay

25 – 26 April 2023

"Grow Beyond Hong Kong" Immersion Programme

  • An exclusive 2-day programme for EPiC 2023 semi-finalists to experience HKSTP’s innovation ecosystem.
  • Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.

28 April 2023

EPiC 2023 Grand Finale

  • Venue: Sky100 Hong Kong Observation Deck
  • Top 50 Semi-Finalists will pitch their ideas within a 60-second elevator ride
  • Top 10 Finalists will pitch their innovation ideas on stage to renowned investors, entrepreneurs, and business leaders
  • All 50 semi-finalists have the golden opportunities to be considered for direct investment of up to US$5 million from the HKSTP Venture Fund, plus the chance to win a cash prize of US$90,000 if crowned overall champion.

For more information on EPiC 2023, please visit: https://epic.hkstp.org/

For full list of the 50 semi-finalists see appendix below.

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at www.hkstp.org.

APPENDIX:

50 semi-finalists for the Grand Finale of EPiC 2023, with 26 from FinTech and 24 from PropTech:

FinTech

Company Name (in alphabetical order)

Headquarter

1

AlgoBot Limited

Hong Kong SAR China

2

Amuro Limited

Hong Kong SAR China

3

Canvasland Limited

Hong Kong SAR China

4

Deland Labs

Singapore

5

Doconomy

Sweden

6

Dowsure

Mainland China

7

Endangered Wildlife OÜ

Estonia

8

FedML, Inc.

United States

9

FinCrime Dynamics

United Kingdom

10

Finema

Thailand

11

FINGREEN AI

France

12

PFY Healthcare Technology

Mainland China

13

Homebase

Vietnam

14

Leapstack

Vietnam

15

Miotech

Mainland China

16

Prometheus Technologies

United States

17

Redkik

United States

18

Revix

United Kingdom

19

Sensor data

Mainland China

20

Health Exchange Technology Service Group

Mainland China

21

Speedlegal

United States

22

Taos Technology LLC

United States

23

Ultipa

Mainland China

24

VoiceAI Technologies

Mainland China

25

Vymo

United States

26

Wequity

Belgium

PropTech

Company Name (in alphabetical order)

Headquarter

1

Archifiction

Mainland China

2

Bridge5 Asia

Singapore

3

Collov, Inc

United States

4

Dfocus

Mainland China

5

Doratoon

Singapore

6

EGG Lighting

United Kingdom

7

Firefly Dimension, Inc.

United States

8

FLX Solutions

United States

9

I2Cool Limited

Hong Kong SAR China

10

IronYun

United States

11

Kodifly Limited

Hong Kong SAR China

12

Layer Construction, Inc.

United States

13

Llewellyn and Partners Company Limited

Hong Kong SAR China

14

Mimicrete

United Kingdom

15

PassiveLogic

United States

16

Photinique Limited

Hong Kong SAR China

17

Rootie

Israel

18

SKYLAND INNOVATION COMPANY LIMITED

Hong Kong SAR China

19

Structure Pal

Israel

20

Swiss AI

Switzerland

21

Tensorflight, Inc.

United States

22

Umi Coating New Material Technology Co., Limited

Hong Kong SAR China

23

Visionaries 777

Hong Kong SAR China

24

VoltSafe Inc.

Canada

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye